Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation
| Autor: | Steffen Rausch, Jörg Hennenlotter, Elke Schaeffeler, Matthias Schwab, Stephan Kruck, Falko Fend, Peter Klaiber, Eva Neumann, Jens Bedke, Kathleen Freitag, Arnulf Stenzl, Marcus Scharpf |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology Cancer Research medicine.medical_specialty Statin Multivariate analysis Adolescent medicine.drug_class medicine.medical_treatment Adrenergic beta-Antagonists Young Adult 03 medical and health sciences 0302 clinical medicine Renal cell carcinoma Internal medicine medicine Humans Hypoglycemic Agents Diuretics Carcinoma Renal Cell Aged Cell Proliferation Neoplasm Staging Aged 80 and over Univariate analysis Tissue microarray Hematology business.industry Cell Cycle Anticoagulants General Medicine Middle Aged Prognosis medicine.disease Kidney Neoplasms Nephrectomy 3. Good health 030104 developmental biology Pharmaceutical Preparations 030220 oncology & carcinogenesis Concomitant Female business |
| Zdroj: | Journal of Cancer Research and Clinical Oncology. 145:1835-1843 |
| ISSN: | 1432-1335 0171-5216 |
| Popis: | Based on the observation of beneficial effects on cancer metabolism, microenvironment, or VEGF-signaling, several non-anticancer drugs have been discussed as useful in renal cell carcinoma (RCC). In the present study, we investigated the prognostic impact of concomitant medication in RCC and correlated comedication with cell-cycle and proliferation activity in corresponding surgical specimen. A total of 388 patients who underwent surgery for localized RCC were included. The individual medication was evaluated according to substance classes. Tissue microarrays from corresponding tumor specimen were immunohistochemically (IHC) stained for Cyclin D1 and Ki67 and semi-quantitatively evaluated. Uni- and multivariate analyses were used to compare survival outcomes. For the comparison of IHC expression according to medication subgroups, Kruskal–Wallis analysis was performed. Median follow-up was 57.93 months (95% CI 53.27–69.43) and median OS accounted for 181.12 months (129.72–237.17). Univariate analysis identified pathological standard variables (T-stage > T2, Grading > G2, L1, N1, M1, sarcomatoid subtype, necrosis) as significant determinants of OS. Moreover, statin use (p = 0.009) and sartan use (p = 0.032) were significantly associated with improved OS. Multivariate analysis identified M1-stage (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink